Litcius/Paper detail

Dostarlimab and niraparib in primary advanced ovarian cancer

Anne‐Claire Hardy‐Bessard, E. Pujade-Lauraine, Richard G. Moore, François Montestruc, Andrés Redondo, Mansoor R. Mirza, D. Cibula, T.-E. Ciuleanu, L. Gilbert, Ram Eitan, Flora Zagouri, S. Pignata, Rosalind Glasspool, Jacobus Pfisterer, Rébécca Phaëton, Charles Anderson, Michele Ângela Rodrigues, Lydia Gaba, E. Bakirtzi, J M Fauci, Elsa Kalbacher, Farida Musa, Samantha Gorman, L. Duska, Laurence Gladieff, P. Braly, Florence Joly, Jessica Thomes Pepin, I. Ray-Coquard, K.N. Moore

2025Annals of Oncology17 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOvarian cancerOncologyPrimary (astronomy)GynecologyInternal medicineCancerAstronomyPhysicsPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies
Dostarlimab and niraparib in primary advanced ovarian cancer | Litcius